Lead: US drug overdose deaths that occurred in isolation, 2022–2024Lead: US drug overdose deaths that occurred in isolation, 2022–2024
This Week in Addiction Medicine from ASAM
This news briefing shares recent research on overdose deaths in isolation, drug market changes, harm reduction services, alcohol screening, and adolescent treatment. It offers concise, evidence-based updates for those interested in addiction medicine and recovery-related care.
7:07•9 Sept 2026
Hard Numbers and New Risks: Overdose, Drug Supply, and Youth Treatment
Episode Overview
- A large majority of recent US overdose deaths occurred in isolation, highlighting the need for overdose education, reversal agents, and monitoring technology.
- Law enforcement disruption of drug markets in San Francisco was linked to people reporting more drug sources, potentially raising overdose risk.
- Community drug checking showed frequent fentanyl detection and unexpected xylazine, indicating many people do not fully know their drug supply.
- Methadone was associated with lower one-year mortality and longer treatment duration than buprenorphine–naloxone among opioid overdose survivors in Ontario.
- Expanding alcohol screening and brief interventions in primary care was projected to reduce alcohol-related premature mortality and narrow socio-economic gaps.
“Of 191,000 overdose deaths, 76% occurred in isolation with no opportunity for rescue.”
What drives someone to seek a life without drugs and alcohol when the data feel so stark? This weekly briefing from "This Week in Addiction Medicine" zooms in on hard numbers and frontline research that shape clinical practice and public health policy.
Hosted by Zach Caruso, the episode starts with a striking statistic from NEJM Evidence: out of 191,577 overdose deaths between 2022 and 2024, "76% occurred in isolation with no opportunity for rescue." Most of these deaths happened in homes, with the authors arguing that better overdose education and wider access to reversal agents could help nearby people step in. For those in complete isolation, the episode mentions technology that monitors vital signs as a potential lifeline.
From there, you’ll hear about how police drug market disruptions in San Francisco are linked to people reporting more drug sources, which may increase overdose risk. A Minnesota study on community drug checking reveals how often people who use drugs don’t know what’s actually in their supply, with fentanyl frequently detected and xylazine showing up unexpectedly.
Caruso also walks through Philadelphia’s response to metatomidine, a new psychoactive substance with severe withdrawal and limited clinical recognition, sharing how local experts met to trade knowledge and refine guidance. For clinicians working with opioid overdose survivors, there’s a key comparison between methadone and buprenorphine–naloxone in Ontario, suggesting different mortality and treatment duration outcomes.
The briefing rounds out with research on expanding alcohol screening and brief interventions in primary care, the dominance of unauthorised e-cigarette sales, and a neuroscience-informed call to rethink adolescent substance use treatment. If you’re short on time but want evidence-based updates on overdose, harm reduction, alcohol-related mortality, and youth treatment, this concise news round-up might be exactly what you’re looking for. Which of these findings could most change the way you think about substance use and recovery?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.